-oxide (TMAO) is a small organic molecule, derived from the intestinal and hepatic metabolism of dietary choline and carnitine. 3 key findings →
Participants: 58 Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
We have defined a new paraneoplastic immunoglobulin G (IgG) autoantibody specific for CRMP-5, a previously unknown 62-kd neuronal cytoplasmic protein of the collapsin response-mediator family. 2 key findings →
Participants: 121 Evidence: low
Full summary, score breakdown and related studies → Original source
Why assessment is of practical consequence to anaesthetistsGeneral Health Questionnaire (GHQ) in general hospitals: selecting a set of items using a stepwise hierarchical procedurePain assessment in cognitively impaired and unimpaired older adults: a comparison of four scalesMental disorders among internal medical inpatientsSuicide in Later Life: A Review and Recommendations for PreventionDELIRIUM IN THE TERMINALLY ILLRecognition of psychiatric disorders in nonpsychiatric hospital wardsNursing documentation versus standardized assessment of cognitive status in hospitalized medical patientsCompleted Suicide Among Older Patients in Primary Care Practices: A Controlled StudyDoes myasthenia gravis affect the brain?SUICIDAL PATIENTS IN THE ED: ETHICAL ISSUESMethodological issues of an epidemiological study: From the results of a study on psychological problems seen in outpatients visiting the internal medicine departments of general hospitalsPsychiatric disorders and vertigoTotal Quality Management and Geriatric CareAssessment and treatment of depression in the cancer patientUse of hospital services by AIDS patients with psychiatric illnessNeuropsychological and Pharmacokinetic Assessment of Hospice Inpatients Receiving MorphineMANAGEMENT OF SUICIDAL BEHAVIOR IN THE ELDERLYLiteraturverzeichnisSuicide in later lifeMajor depression in the primary care settingMaking the diagnosis of depression in the primary care settingThe Mini-Mental State Examination in General Medical Practice: Clinical Utility and AcceptancePsychological Morbidity in Obstetric-Gynaecology Patients: Testing the Need for Expanded Psychiatry Services in Obstetric-Gynaecology FacilitiesPrevalence of Psychiatric Disorders in Medical InpatientsTranstornos do humor em enfermaria de clínica médica e validação de escala de medida (HAD) de ansiedade e depressãoDelirium in Elderly Patients: Evaluation and ManagementDelirium Presenting With Symptoms of DepressionAnalysis of the terms used by general practitioners to characterize patients considered by them as depressed.
Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source
48/100
In 2004, a total of 2,397,615 deaths were reported in the United States. 5 key findings →
Participants: 2,397,615 Evidence: low
Full summary, score breakdown and related studies → Original source
Apathy was significantly associated with older age (p = 0.009), and a higher frequency of minor and major depression (p < 0.0001). 3 key findings →
Participants: 354 Evidence: low
Full summary, score breakdown and related studies → Original source
In relation to placebo, the last observation in phase 1 showed greater improvement with olanzapine or risperidone on the Neuropsychiatric Inventory total score, risperidone on the Clinical Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rating Scale (BPRS) hostile suspiciousness factor, and risperidone on the BPRS psychosis factor. 5 key findings →
Design: clinical trial Participants: 421 Evidence: low
Full summary, score breakdown and related studies → Original source
48/100
The mean age was 51 ± 12 years. Forty-two of the patients had OSAS. 5 key findings →
Participants: 73 Evidence: low
Full summary, score breakdown and related studies → Original source
The predefined superiority of donepezil to the placebo was not confirmed in either active group in the primary analysis. 5 key findings →
Participants: 142 Evidence: low
Full summary, score breakdown and related studies → Original source
Tau pathology is a hallmark of several neurodegenerative diseases, including frontotemporal dementia and Alzheimer's disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
48/100
The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The NULISA multiplexed platform produces reliable results for established biomarkers in CSF that are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We investigated whether the cerebrospinal fluid (CSF) biomarkers beta-amyloid 1-42 (Abeta1-42), total tau (t-tau) protein and tau protein phosphorylated at threonine 181 (p-tau181) could discriminate Alzheimer's disease (AD) from vascular dementia (VD) patients. 4 key findings →
Participants: 35 Evidence: low
Full summary, score breakdown and related studies → Original source
The prevalence of epilepsy is increased among Alzheimer's Disease (AD) patients and cognitive impairment is common among people with epilepsy. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings indicate that GFAP is of potential clinical utility in screening amyloid pathology and predicting future cognitive decline. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We underline the potential of next-generation biomarker identification tools to detect novel proteomic features that also incorporate established biomarkers. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In the community, the concentration of AD blood biomarkers varies in relation to medical conditions and systemic inflammation. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The levels of plasma ATN biomarkers (Aβ42/Aβ40 ratio, p-tua181, and NfL) were significantly changed in clinically diagnosed AD patients and they all associated with different domains of cognitive impairment. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The choice of tau biomarker may differ by disease stage and research goals that seek to maximize sensitivity or specificity. 2 key findings →
Participants: 351 Evidence: low
Full summary, score breakdown and related studies → Original source
Oligomeric-Aβ mediates the maturation of tau pathology and its neuronal toxicity in macaques but not its initial spreading. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This ITR analysis provides a proof of concept for precision medicine in future AD research and drug development. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings provide evidence that greater concentrations of KP metabolites are associated longitudinally over two years with greater biomarker evidence of neurofibrillary tau pathology (pTau-181), neuroinflammation (GFAP), and neurodegeneration (NfL), suggesting that dysregulated KP metabolism may play a role in ADRD pathogenesis. 4 key findings →
Participants: 301 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma BD-tau is a valuable marker for CJD prognostication. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Men and women with MCI may to differ for which factors predict subsequent dementia although future analyses with greater power are needed to evaluate sex differences. 5 key findings →
Participants: 449 Evidence: low
Full summary, score breakdown and related studies → Original source
Lobar distribution of cerebral microbleeds is associated with Alzheimer's disease and the number of lobar cerebral microbleeds directly correlates with cerebrospinal fluid amyloid-beta and phosphorylated tau 181 protein levels and with the cognitive decline of Alzheimer's disease patients. 2 key findings →
Participants: 54 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma biomarkers for Alzheimer's disease (AD), such as plasma phosphorylated (p)-tau217, offer a more accessible means of testing for the presence of AD pathology compared to cerebrospinal fluid (CSF) or positron emission tomography (PET) methods. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →